ABO-201
/ Arbor Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 21, 2026
Arbor Biotechnologies, Inc…announced the nomination of three CNS-focused development candidates: ABO-201 for familial ALS, and ABO-202 and ABO-203 for sporadic ALS.
(GlobeNewswire)
- "First CNS investigational new drug (IND) filings are anticipated in 2027."
IND • New molecule • Amyotrophic Lateral Sclerosis
1 to 1
Of
1
Go to page
1